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Allogeneic hematopoietic stem cell transplantation is mainly indicated in bone marrow dysfunction related to
blood diseases, but also in some rare diseases (adrenoleucodystrophy, mitochondrial neurogastrointestinal
encephalomyopathy or MNGIE…). After decades, this treatment has proven to be efficient at the cost of
numerous early and delayed side effects such as infection, graft-versus-host disease, cardiovascular complications
and secondary malignancies. These complications are mainly related to the conditioning, which requires a powerful
chemotherapy associated to total body irradiation (myelo-ablation) or immunosuppression (non myelo-ablation).
Among side effects, the endocrine complications may be classified as 1) hormonal endocrine deficiencies (particularly
gonado- and somatotropic) related to delayed consequences of chemo- and above all radiotherapy, with their
consequences on growth, puberty, bone and fertility); 2) auto-immune diseases, particularly dysthyroidism; 3)
secondary tumors involving either endocrine glands (thyroid carcinoma) or dependent on hormonal status
(breast cancer, meningioma), favored by immune dysregulation and radiotherapy; 4) metabolic complications,
especially steroid-induced diabetes and dyslipidemia with their increased cardio-vascular risk. These complications
are intricate. Moreover, hormone replacement therapy can modulate the cardio-vascular or the tumoral risk of patients,
already increased by radiotherapy and chemotherapy, especially steroids and anthracyclins… Therefore, patients and
families should be informed of these side effects and of the importance of a long-term follow-up requiring a
multidisciplinary approach.
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La transplantation allogénique de cellules souches hématopoïétiques est pratiquée dans les dysfonctions de moelle
osseuse liées à des hémopathies, mais également dans certaines maladies rares (adrénoleucodystrophie,
encéphalomyopathie mitochondriale gastro-intestinale ou MNGIE…). Après quelques décennies, ce traitement a fait
la preuve de son efficacité au prix d’un certain nombre d’effets secondaires précoces ou plus tardifs tels qu’infection,
réaction greffon-contre-hôte, complications cardiovasculaires et cancers secondaires. Ces complications sont
principalement liées au conditionnement, qui requiert une chimothérapie puissante associée à une irradiation
corporelle totale (conditionnement myélo-ablatif) ou une immunosuppression (conditionnement non myélo-ablatif).
Parmi ces effets secondaires, les complications endocrines peuvent être classées en 1) déficits hormonaux endocrines
(particulièrement gonado- and somatotropes) liés aux conséquences de la chimio- et surtout de la radiothérapie, avec
ses effets propres sur la croissance, la puberté, l’os et la fertilité; 2) maladies auto-immunes, particulièrement
dysthyroidies; 3) tumeurs secondaires impliquant soit les glandes endocrines (cancer thyroidien) ou dépendant du
statut hormonal (cancer du sein, méningiome), favorisées par la dysrégulation immunitaire et la radiothérapie; 4)
complications métaboliques, spécialement diabètes cortico-induits et dyslipidémies qui s’accompagnent d’un risque
cardiovasculaire accru. Ces complications sont intriquées. De plus, l’hormonothérapie substitutive peut moduler le
risque cardio-vasculaire et tumoral de ces patients, déjà accru par la radiothérapie et la chimothérapie, notamment les
glucocorticoides et les anthracyclines… C’est pourquoi ces personne et leur famille doivent être informées de ces effets
secondaires et de l’intérêt d’un suivi multidisciplinaire à long-terme.
Mots-clés: Transplantation de moëlle osseuse, Allogreffe de cellules souches hématopiétiques, Complications
endocrines, Insuffisance gonadique, Hypothyroidie, Ostéoporose, Diabète, Dyslipidémie, Risque cardiovasculaire,
Cancers secondairesIntroduction
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) has become the treatment of choice for a variety
of hematological disorders as well as for some rare dis-
eases such as adrenoleucodystrophy and mitochondrial
neurogastrointestinal encephalomyopathy (MNGIE). With
the increased number of long-term survivors, attention is
now focused on the early and late transplant-related com-
plications, which not only can be life-threatening, but also
may worsen quality of life of patients [1,2].
In addition to well-known secondary cancer and cardio-
metabolic disorders, endocrine dysfunctions have been de-
scribed in both children and adults in combination with
bone complications. Recipient age, underlying disease and
transplantation modalities, specifically conditioning regi-
men (chemotherapy, total body irradiation (TBI)) and
graft-versus-host disease (GVHD) prophylaxis (immuno-
suppression, steroids), influence the occurrence of such
complications [3-6]. In gross, endocrine complications may
be classified into 1) hormonal endocrine deficiencies (par-
ticularly gonado- and somatotropic influencing growth,
puberty, bone and fertility); 2) auto-immune diseases,
particularly dysthyroidism [7]; 3) secondary tumors,
the risk of which is 24 fold higher [8] compared to the
general population, involving either endocrine glands
(thyroid carcinoma) or dependent on estrogen and
progestin (breast cancer, meningioma); 4) metabolic
complications, especially steroid-induced diabetes, asso-
ciated to increased cardio-vascular risk. This last group of
complications is less specific and may be encountered inall types of transplantation, even if the cardiovascular risk
seems worserned by TBI. Moreover, hormone replace-
ment therapy can modulate the cardio-vascular or the tu-
moral risk of patients.
Five to 10% of patients die of non-relapse causes at a
median of 5 years post allo-HSCT (mainly chronic GVHD,
secondary malignancy and infection) [9]. The late endo-
crine and metabolic complications are hypogonadism in
one third of patients, osteopenia/osteoporosis and hyper-
tension in 20 to 25%, and hypothyroidism, dyslipidemia,
diabetes and sexual dysfunction in 5 to 10% of 10-year
survivors [9]. A careful monitoring of these intricate com-
plications is warranted and requires a multidisciplinary
approach.
The main aim of this article is to give an overview on
transplant-related endocrine dysfunctions. Our meth-
odological approach consisted in a PubMed review using
the following key-words: hematopoietic stem cell trans-
plantation and hypogonadism, thyroid, pituitary, adrenal,
bone, iron overload, lipodystrophy, diabetes, dyslipidemia
and cardiovascular risk. A multidisciplinary discussion
was held based on this literature review and the clinical
experience of each author.
Endocrine complications
Post-transplant gonadal failure
Central or peripheral gonadal failures (i.e. premature
ovarian and testicular failure) are frequent complications
of allo-HSCT [10]. Gonadal failure can lead to sex-
steroid deficiencies, resulting in infertility. Furthermore,
Table 1 Main techniques of fertility preservation
Techniques
Ovarian cortex freezing - for future orthotopic graft or
- in vitro follicular maturation if a
graft is not possible because of
the risk of re-introducing dormant
cells
- can even be performed in an
emergency
Oocyte cryopreservation after a
conventional in vitro fertilization
stimulation protocol
- specially indicated in young,
single female patients (live birth
rate: 1% to 2%)
- but time for stimulation needed
before radio/chemotherapy
In vitro fertilization and embryo
freezing
- currently the best preservation
technique
- requires 3 weeks for the ovarian
stimulation and thus will only be






- easy to perform, even in an
emergencuy context
Transposition of the ovaries prior
to radiotherapy.
If the planned treatment is highly
gonadotoxic, it is possible (and
indeed advisable) to transpose one
ovary and freeze the other.
Indications
Young girl ovarian freezing only possible
option
Pubertal girl and /or woman under
the age of 40:
all of the above-listed techniques
can be considered.
Single women, oocyte cryopreservation and
ovarian cortex freezing preferable
Table 2 Induction of amenorrhea
1. GnRH agonist (3.75 mg/month subcutaneous leuprolide acetate,
in general), enabling
a. induction of amenorrhea
b. “parenteral” contraceptive effect effective even in patients with
vomiting
c. possible anti-apoptotic, protective effect on the follicles,
observed in animal studies but not yet in women.
2. In order to avoid flare-ups, it is recommended to prescribe
a. a contraceptive pill 10 to 15 days after the agonist injection
b. or a macroprogestin for the first month.
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ation related to significant alteration of the vascular bed.
In the event of pregnancy, the risk of intra-uterine
growth retardation, prematurity and uterine rupture is
increased. Lastly, children having received an allo-HSCT
can present failure to thrive and delayed puberty.
Main factors of gonadal failure
Gonadal failure mainly depends on the conditioning
treatment. High-dose busulfan, TBI and testicular irradi-
ation are responsible for gonadal failure. Although most
of the literature series are modest in size, the frequency
of delayed puberty is evaluated to be 10% after exposure to
cyclophosphamide, 35% after cyclophospamide-busulfan
combination therapy, 65% after (10 gray) TBI, and 80%
if testicular irradiation is also required.
Alkylating agents such as procarbazine and cyclo-
phosphamide induce prolonged azoospermia in over 90%
of men and premature ovarian failure in 5%-25% of
women under the age of 30. The risk of infertility increases
with a younger age of treatment and the cumulative
dose of alkylants. Doxorubicin-bleomycin-vinblastine-
dacarbazine chemotherapy is associated with a limited
risk of premature ovarian failure and infertility (below
10%).
Overall, large epidemiological studies have revealed the
risk of infertility to be at least 40% at age 35 regardless of
the age at the time of chemotherapy and even after full re-
covery of the initial follicular reserve [10,11].
Diagnosis
On the biochemical level, hormone deficiency favors
dyslipidaemia and insulin resistance. Blood testoster-
one and oestradiol levels are abnormally low and plasma
gonadotropin levels (LH and FSH) are high. Gonadotropin
levels may be intermediate or low in cases of additional
gonadotropin deficiency. It is essential to rule out other
causes of amenorrhea, such as hypothalamic amenorrhea
or polycystic ovary syndrome. Low anti-Müllerian hor-
mone (AMH) blood levels reflect a low ovarian reserve
and provide information on fertility [12].
Preservation of fertility
Cryopreservation of sperm must be considered prior to
cytotoxic treatment (i.e. the chemotherapy and/or irradi-
ation) in post-pubertal boys. As soon as the disease has
been diagnosed, a female patient must be informed about
infertility risk associated with cytotoxic treatments and
about fertility preservation techniques that can be applied
in her particular situation [13-16] (Table 1).
Induction of amenorrhea in female transplant recipients
In menstruating women, the induction of amenorrhea use-
fully decreases the risk of hemorrhage when the plateletcounts falls. The most current approach involves adminis-
tration of a GnRH agonist, which also provides a protective
effect on ovarian reserve (Table 2).
Corticotropin deficiency following corticosteroid therapy
Main factors of corticotropin deficiency
The prolonged use of glucocorticoids can lead to cor-
ticotropin deficiency via inhibition of the production of
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and pituitary ACTH. Generally, this corticotropin defi-
ciency resolves spontaneously once steroid therapy is
withdrawn, except when the treatment is prolonged or
involves high doses. Corticotropin deficiency can also be
caused by TBI; this often develops over several years and
may be accompanied by other pituitary hormone defi-
ciencies [17]. Last but not least, numerous drugs inhibit-
ing the cytochrome p450, such as macrolides or antifungal
drugs, can interfere with steroid metabolism, especially
fluticasone and budesonide metabolism, inducing a clin-
ical pseudo-Cushing syndrome contrasting with a bio-
logical profile of corticoptropin deficiency.
Diagnosis
The symptoms of chronic adrenal dysfunction in bone mar-
row transplant recipients can mimic graft-versus-host reac-
tion, inasmuch as they include fatigue, weakness, anorexia,
nausea, vomiting, weight loss, and orthostatic hypotension.
The clinical diagnosis of these insidious forms is often prob-
lematic and the physician should not hesitate to run labora-
tory tests, especially morning blood cortisol.
The steps of biological diagnosis are given in Figure 1.
Treatment
When a corticotropin deficiency has been confirmed by
laboratory test results, it is advisable to replace synthetic
corticosteroids by 20 mg/day of natural hydrocortisone,
if the intention was to stop synthetic cortico-steroids,
and to introduce 20 mg/day of hydrocortisone in two
separate doses if the patient was not treated (cortico-
tropin deficiency post-radiotherapy). In fact, hydrocorti-
sone has a much shorter half-life and less suppressive
activity than synthetic glucocorticoid and may enable
the recovery of normal corticotropin function after just
a few weeks or as much as one year [18] (Figure 1).
Otherwise, the patient should be advised to increase his
or her steroid dose in case of intercurrent event (infec-
tion, surgery or even hot weather…).
Post-transplant thyroid disorders
Disorders of thyroid function
Besides TBI and immunosuppressive drugs (tyrosine
kinase inhibitors, bexarotene, alemtuzumab, interferon
alpha, ipili- and iremeli-mumab, thali- and enali-domide)
[19]), amiodarone, radiological contrast medium, iodine
antiseptic solutions might participate in thyroid dysfunc-
tion by massively increasing iodine supply.
Hypothyroidism Primary hypothyroidism occurs in about
50% of irradiated patients in the year following radiother-
apy. The incidence is proportional to the dose received and
the youngest age of treatment. Hypothyroidism may be
compensated or transient and the long-term incidence isabout 20% [20-22]. Although peripheral hypothyroidism is
the most frequent manifestation, thyrotropin deficiency
(after bexarotene treatment), and anomalies of the per-
ipheral metabolism of thyroid hormones may also be
encountered.
Given the difficulty of diagnosing hypothyroidism in
patients whose complaints (asthenia, cold intolerance,
etc.) can easily be attributed to the causal disease or
chemotherapy itself, it is important to regularly monitor
not only plasma thyroid-stimulating hormone (TSH),
but also free T4 values. Moreover, taking into account
the sometimes fluctuating values of TSH in these pa-
tients, it is important to keep in mind that isolated, mild
increase of TSH below 10 mUI/L should always be con-
firmed a second time before making a treatment decision,
according to the recommendations of hypothyroidism
treatment [23,24]. Otherwise, the administration of iron
per os must not be given at the same time as replacement
hormone therapy with L-thyroxine since it alters the
absorption of the hormone by interfering with the
entero-hepatic cycle of bile acids.
Hyperthyroidism The donor-recipient transfer of B and T
lymphocytes may favor the occurrence of hyperthyroidism
(Graves disease, sometimes preceded by a hypothyroid
episode related to blocking anti-TSH receptor antibodies or
immune reconstitution syndrome). However, the disappear-
ance of an autoimmune disease has also been reported [25].
Iodine overload can also promote hyperthyroidism and
stress may trigger the appearance of Basedow’s disease.
Thyroid nodular dystrophy
The 10-year cumulative incidence of thyroid nodules in
ultrasound sonography in children after TBI is estimated
at 16%, half of them potentially malignant. Ten-year post-
HSCT is the median time of occurrence [22].
Thyroid cancer
In a large retrospective European study of allo-HSCT in-
cluding about 69,000 cases, the relative risk of thyroid
cancer was three-fold higher than in the general popula-
tion. A multivariate analysis showed that the younger
the patient’s age at transplantation, the greater the risk
(with relative risks greater than 20 before the age of 10
and nearly 5 between the ages of 11 and 20). Irradiation,
female gender and the presence of a GVHD were also
identified as risk factors. A third of the patients were
asymptomatic when thyroid cancer was discovered and
all but one of the 32 patients responded to standard
treatment (thyroidectomy and iodine-131 therapy) [26].
Therefore, this higher incidence of thyroid cancer was
not associated with a worse outcome after allo-HCST, as
also demonstrated after transplantation even if the initial
presentation was more aggressive [27,28].
Figure 1 Corticotropin deficiency.
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TBI can trigger late-onset anterior pituitary deficiency oc-
curring 2 to 10 years after treatment and slowly worsening
over time. The onset of these corticotropin (see above), go-
nadotropin, thyreotropin, somatotropin deficiencies is very
insidious and is often revealed by non-specific asthenia,
paleness, hair thinning, a loss of libido and (in menstruat-
ing women) oligo- or a-menorrhoea. On the biochemical
level, pituitary as well as thyroid, adrenal or sex hormone
levels do not drop sharply but tend to fluctuate around
low-normal values. Dynamic tests in a specialized endo-
crinology clinic are often required for confirmation of the
diagnosis and adjustment of the treatment.
Corticotropin deficiency
Besides post-steroid corticotropin deficiency, TBI can
also induce pituitary damage, with an ACTH deficiency,
which will be confirmed either with a low dose cortico-
tropin test or with a hypoglycaemic or a metyrapone test
performed in a specialized clinic. The treatment with
hydrocortisone may unveil thyrotropin deficiency, which
should always be checked after hydrocortisone replace-
ment therapy.
Thyroid dysfunction
The blood TSH level is below 5 mIU/L and free T3 and
free T4 levels are low-normal or below normal. The
treatment must be initiated progressively – especially
when the person is elderly or has underlying coronary
disease and when the deficiency has been present for
some time. This is done to reach free thyroid hormone
levels within the upper quartile of the normal range. In
fact, a TSH assay is of little value to adapt treatment in
central hypothyroidism.
Somatotropin deficiency
Young age at irradiation and the absence of dose frac-
tionation in TBI are predictive of growth hormone (GH)
deficiency and growth retardation in 20-50% of the pa-
tients having received brain irradition or TBI in addition
to chemotherapy. This deficiency results in small adult
height stature, which may also be favored by skeletal
anomalies and gonadal failure [29,30].
An undetectable GH concentration and low plasma
IGF1 concentration, which does not exceed 3 ng/ml
after stimulation, are suggestive of somatotropin defi-
ciency. If treatment is considered (particularly in chil-
dren with growth retardation), it is necessary to perform
two dynamic tests in a specialist clinic. It is important to
note that GH therapy has been shown to help gain +1.1
SD of height after 5 years, whatever the GH secretion
status was before treatment [31]. Nevertheless, as this
treatment type can only be administered after the initial
disease has been controlled, the indication of the treatmentshould be carefully weighed. In adulthood, a severe alter-
ation in overall health status due to somatotropin defi-
ciency may prompt consideration of GH treatment. Given
that the literature’s data are contradictory about the risk of
cancer recurrence, it appears wise to only suggest this
treatment when the clinical impact is severe and when
close monitoring is possible.
Gonadotropin deficiency
As described above, low oestrogen or testosterone levels
and non-elevated gonadotropins levels are suggestive of




Adenomatous hyperparathyroidism is a rare but well-
known complication of radiotherapy [32] and should be
considered after the discovery of osteopenia or kidney
stones. Referral for thyroid disease is another frequent
circumstance of diagnosis (10% of these patients also
have a parathyroid adenoma) [33]. Besides the mutagen
effect of TBI, a chronic stimulation of PTH in response
to the irradiation-altered bone marrow microenviron-
ment, could also favor hyperparathyroidism, often all the
more so when kidney function is altered [34].
Osteoporosis
Gonadal failure, corticosteroid therapy, the lack of phys-
ical activity engendered by asthenia, denutrition and
vitamin D deficiency are all risk factors for osteoporosis
in light of advice to avoid sun exposure is given to pre-
vent skin cancer in cases of TBI [35].
In a French prospective multicentric cohort of child-
hood leukemia survivors, transplantation with gonadal
insufficiency and female gender where the 2 main factors
associated with lower femoral bone mineral density,
whereas the adult patients had a slight reduction in lum-
bar bone mineral density, whatever their transplantation
status [36]. Concerning chimiotherapy, only high-doses
cause osteoporosis with respectively a 10% and 20% loss
in cortical and trabecular bone by altering bone progeni-
tors [37]. This condition can be worsened by somatotropin
deficiency, hyperthyroidism or additional hyperparathyr-
oidism. It is thus essential to prevent osteoporosis – and
perhaps GVHD [38], by providing sufficient vitamin D sup-
plementation (100,000-unit dose of oral cholecalciferol
monthly, together with 500 mg to 1 g of calcium per day
or a sufficient intake of dairy products (two yogurts and
30 g of cheese providing about 600 mg of calcium/day).
The treatment of gonadal insufficiency is essential [39].
Screening with dual-energy X-ray absorptiometry is
useful when several risk factors are present. Levels of
bone remodeling markers (osteocalcin and procollagen
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carboxy-terminal telopeptide of type I collagen or CTX
for resorption) do not change significantly [40].
Lipodystrophies and metabolic syndrome
GVHD sometimes prompts the appearance of localized
lipodystrophies – particularly in subcutaneous abdom-
inal tissue, which takes on an infiltrated, cellulite-like,
orange-peel aspect. Given that adipose tissue is a key
player in innate immunity and the regulation of insulin
resistance, it is possible that these acquired lipodystro-
phies result from the immune deregulation induced by
transplantation and are involved in the pathogenesis of
metabolic syndrome [41]. mTOR inhibitors block the
maturation of adipocytes, which may mean that the lat-
ter drug will be of particular value for the treatment of
this type of lipodystrophic GVHD.
Iron overload
Outside of the specific problem of ß thalassemia, hyper-
ferritinemia is found in 93% of children one year after
allo-HSCT but diminishes with time. Hyperferritinemia
is correlated with gamma glutamyl-transferase levels and
is a well-known factor of liver insulin resistance, but also
insulinopenia and therefore diabetes. Iron overload, better
assessed by liver MRI than by blood ferritin level, is
probably involved in endocrine dysfunction, since it
is significantly greater in patients suffering from
hypothyroidism or a somatotropin deficiency. Nevertheless
its influence on overall mortality has been diversely
appreciated according to the tool used to assess it
(ferritin or MRI), the time of assessment (pre- orTable 3 Metabolic syndrome and cardiovascular risk factors
Metabolic syndrome
- insulin resistance
- pro-thrombotic, inflammatory state
- high blood pressure
- changes in the distribution of adipose tissue
- dyslipidemia characterized by hypertriglyceridemia (above 1.5 g/L)
and low HDL cholesterol levels (<0.4 g/L in male and 0.5 g/L in
female). leading to early-onset cardiovascular disease.
NB: Role of immunosuppressive regimen
- Glucocorticoid therapy increases total cholesterol, VLDL, the size and density
- Calcineurin inhibitors reduce clearance of athero- genic lipoproteins by incre
- Ciclosporine, metabolized through CYP3A4, induces a greater adverse impac
exposure
- Sirolimus causes dyslipidaemia in 50% of casespost-allo-HSCT) and finally the period considered for
outcome. No association was found between pretransplant
MRI-assessed iron overload and 1-year allo-HSCT out-
comes [42], whereas post-HSCT hyperferritinemia or
MRI-iron overload has been shown to have a detrimental
effect on 5-year outcomes [43,44]. Therefore, this
condition may necessitate treatment (usually careful
bloodletting, or sometimes iron chelators) when it is
symptomatic, persistent, and confirmed by liver-MRI.
Anomalies of iron metabolism also influence FGF23
and phosphorus-calcium metabolism. Indeed intraven-




Many transplanted patients develop diabetes and or glu-
cose intolerance despite the absence of being overweight
or a family history of diabetes. The cumulative incidence
of diabetes plus glucose intolerance was recently estimated
at 11% at 5 years and 69% 10 years after allo-HSCT. A
higher preprandial glucose level in the peri-HSCT and an
age ≥6 year-old at the time of HSCT are predictive factors
of glucose tolerance disorders [46]. High doses of steroids,
increase insulin resistance and certain immunosuppressive
agents used to treat GVHD (such as calcineurin and
mTOR inhibitors) inhibit insulin secretion and/or modu-
late insulin resistance [47]. Furthermore, 80% of patients
having received radiotherapy display insulin resistance
and 60% dyslipidemia. An increase of the body’s fat mass
(especially the visceral adipose tissue), possibly promoted
by a GH deficiency, is involved in the pathogenesis ofCardiovascular risk factors
- family history of early-onset coronary heart disease: myocardial
infarction or sudden death of the father or a first-degree male relative
before the age of 55 or of the mother or a first-degree female relative
before the age of 65 or stroke in a family member before the age
of 45.
- on-going tobacco use or cessation within the last three years.
- hypertension (even when treated).
- HDL-cholesterol <0.4 g/L (NB: values >0.60 g/L are protective).
- Microalbuminuria >30 mg/24 h.
- Age >50 in men, >60 in women + history of transplantation
of LDL particles and TG by increasing insulin resistance.
asing the activity of hepatic lipase and decreasing lipoprotein lipase.
t on lipid profiles than tacrolimus, and may increase systemic statin
Table 4 Diagnosis of diabetes and blood glucose monitoring guidelines
Diagnosis of diabetes - glycaemia ≥2 g/L, associated with clinical signs
- fasting blood glucose ≥1.26 g/L on two occasions
- blood glucose ≥2 g/L 2 hours after OGTT
HbA1c >6% - should trigger more frequent blood glucose monitoring,
- given that the anemia frequently observed in transplant patients
can alter HbA1c
In patients with weight loss, thirst and polyuria (particularly at night), - capillary blood glucose monitoring must be performed
- before a meal and two hours thereafter
- with a ketone research.
If 2 capillary blood glucose values >1.50 g/L, - monitoring must be continued
- regardless of whether or not the patient is symptomatic.
When corticosteroid therapy is initiated - check postprandial blood glucose ++
- may be elevated even when pre-prandial glycaemia is
normal regardless of the clinical signs.
During a steroid therapy step-down phase - frequent monitoring recommended, to avoid hypoglycemia.
During the period of insulin adjustment - capillary glycaemia should be monitored
- 6 x/day (before each main meal and 2 hours thereafter).
If not possible to obtain regular self-monitoring - try to obtain 6 or 7 measurements over 2 or 3 days
- or refer the patient for a 3- to 7-days continuous
ambulatory glucose monitoring
When nocturnal enteral nutrition is initiated, - perform 1 or 2 night-time and a morning capillary blood
glucose to adjust the evening dose of insulin.
Once the treatment parameters have stabilized, monitoring can be relaxed, with measurement of pre-prandial and postprandial glycaemia (at 2 hours) after one of the
day’s meals.
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low adiponectin levels [48,49]. Indeed, the occurrence of
post-HSCT diabetes is also related to altered immune
regulation, especially of Tregs [50] and could be associated
with more frequent GVHD [51].
The term “metabolic syndrome” defines a clustering
of cardiovascular risk factors, defined by the National
Cholesterol Education Program Adult Treatment Panel
III, as the simultaneous occurrence of at least three of
the following: abdominal obesity, arterial hypertension,
hyperglycemia, hypertriglyceridemia and low high-density
lipoprotein cholesterol (HDL-C) (Table 3). Its prevalence
is increased after allo-HSCT and its main risk factors are
high insulin and leptin levels, older age and hypogonadism
[52]. Metabolic syndrome is also favored by stress, lack of
physical activity, enteral nutrition, which sometimes leads
to liver steatosis [53], gonadal hormone deficiency and
(when repeated transfusions are necessary) iron overload.Table 5 Dietary principles in case of diabetes
A consultation with a dietician is
needed so that patient learns to: 1.
identify low glycaemic index food,
2. limit the intake of high glycaemic
index food especially between meals
High-calorie, low glycaemic index
foods should be favoured (oleaginou
foods, rice pudding, complex
carbohydrate-lipid mixtures etc.…).Consultation with a diabetologist is notably required
in patients who were diabetic before transplant and
those who present poorly controlled steroid-induced dia-
betes. In this context, the goal of diabetes treatment is
to maintain glycaemia between 0.80 and 1.50 g/L and
thus minimize polyuric syndrome, water balance/electro-
lyte disorders, denutrition, infection and the risk of
hypoglycemia.
The criteria diagnosis of diabetes and the blood glu-
cose monitoring, dietary, oral anti-diabetic and insulin
treatment guidelines are detailed in Tables 4, 5, 6 and 7,
in order to enable a non-specialist to provide sufficient
care in a patient who is given steroids and/or who re-
veals post-transplant diabetes. The adjustment of steroid
dose and/or immunosuppressive regimen might some-
times resolve the hyperglycaemic state. Diet should never
unduly be hypocaloric even if restricted in saturated fat or
high glycaemic index food. Otherwise, to start insulins
Insulin therapy and self-monitoring
must be adapted to suit the patient’s dietary
habits (small, frequent meals rather than few,
large meals a day and gastrointestinal GVHD
modulating digestive tolerance




Table 6 Guidelines for treatment of post-transplant diabetes
Oral antidiabetic agents have not been studied in terms of efficacy and safety
in transplant recipients, pediatric recipients in particular.
Insulin therapy is preferred in all unstable situations
because of its anabolic effect. The objective is to tailor
the insulin therapy to food habits, in order to limit
weight loss
Most antidiabetic agents
contraindicated in cases of
kidney failure and cholestasis.
In contrast, acarbose despite digestive side effects and
glinides can be useful.
- slow-acting insulin (often an insulin analogue like
detemir (12 hours) or glargine (24 hours))
- Metformin: risk of lactic
acidosis.
Repaglinide (0.5 mg to 4 mg before each snack) can
be used instead of injections of ultra-rapid insulin
(particularly in patients on low doses of steroid).
- rapid-acting insulin (lispro, aspart or glulisine)
(2 hours) or regular insulin (4 hours) administered at
meal times.
- Sulphamides with a long
half-life (such as gliclazide)
increase the risk of
hypoglycemia.
- NB: ultra-rapid insulin (lispro, aspart or glulisine) can be
administered immediately after the end of the meal,
when the food intake is somewhat unpredictable
NB
- Gliptins sometimes lead
to pancreatitis
- Change regularly insulin injection site, to avoid
lipodystrophy.
- GLP-1 agonists promote nausea
and weight loss.
- Adapt length of the needle: 4–5 mm if body
weight <40 kg, 6 in a lean, 8 in a normal-weight
and 12 mm in an obese person.
- The patient must learn to recognize and treat symptoms
of hypoglycemia:
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prandial blood glucose levels are the first to increase with
steroids and their monitoring should not be skipped even
if fasting blood glucose is normal.
Hyperlipidemia
In a retrospective analysis of around 350 allo-HSCT re-
cipients, half had a blood cholesterol value over 2 g/L
three months post-transplantation. The median cholesterol
and triglyceride levels had increased by one third and two
thirds respectively in adults, and by 50% and 100% respect-
ively in children relative to pre-transplantation values. Se-
vere hypertriglyceridemia was observed in about 5% of
adults and 8% of children.
Dyslipidemia is associated with poor survival in organ
transplant recipients. Even after the discontinuation of im-
munosuppression and adjustments for age, gender andTable 7 Adjustment of insulin therapy
Rapid-acting insulin
3 methods for adjusting rapid-acting insulin
Retrospective (sliding scale) - the
simplest- given dose according to
pre-prandial blood glucose
Anticipatory Fun
- insulin dose according to
postprandial glycaemia observed




- more complex to use but - po
ins
- more appropriate if steroids useobesity, allo-HSCT recipients appear to be at a higher risk
for diabetes and hypertension than their siblings. An early
onset cardiovascular disease can occur, which is driven
directly by TBI-related atherosclerosis and chemotherapy-
linked cardiomyopathy, especially with anthracyclins, and
driven indirectly by post-transplant metabolic syndrome.
Cardiovascular risk
Indeed, some recent clinical cases have shown the occur-
rence of early, fatal coronary heart disease and congest-
ive heart failure, at a median age of 35, with a median
time of death 7.5 years after transplantation [54].
In a retrospective cohort study, transplant recipients
with a survival of at least 2 years experienced increased
cardiovascular death and cumulative incidence of ische-
mic heart disease, heart failure, stroke, vascular diseases,
and rhythm disorders. These patients also had a higherLong-lasting basal insulin
ctional Only when pre-prandial glucose >1.20 g/L
or when the patient loses weight
ulin dose based on counting
rbohydrates - complex
- usually 2 detemir injections
- or a single glargine injection in the
evening at a total dose of 0.3 to
0.5 U/kg/day.
orly suited to transient
ulin therapy
- Any increase in pre-prandial glycaemia
(particularly in the morning) >1.50 g/L
necessitates an increase of 2 to 4 units
in the dose of slow-acting insulin
relative to the previous day.
Table 9 Screening of metabolic complications and management of dyslipidemia (see Tables 5 and 6 for diabetes
management)




- Fasting blood glucose, HbA1c
2. Prior to treatment, rule out hypothyroidism, nephrotic
syndrome and cholestasis, by checking
- TSH, free T4
- 24-hour proteinuria,
- bilirubin and alkaline phosphatases
3. Then treat according to the cardiovascular risk (factors
listed in Table 9),
- If high cardiovascular risk, dyslipidaemia must be treated.
- If low cardiovascular risk, treat according to
- severity of dyslipidemia
- prognosis of the transplantation.
- liver enzyme profile.
4. Adjust treatment according to LDL cholesterol and
triglycerides levels
- Dietary and lifestyle measures always advisable.
- Modify the dose of immunosuppressantif possible as the 1st step
- If LDL cholesterol high and triglycerides <2 g/L: statin at the lowest dose to
limit toxicity. NB pravastatin and fluvastatin, metabolized through alternative
pathways = best choice in patients requiring co-administration of cytochrome
P3A4 inhibitors
5. If mixed hyperlipidaemia or resistance to statin, add - ezetimibe to statins, rather than increase the statin dose.
- fibrates but increases the risk of muscle disorders
6. If isolated hypertriglyceridemia >8 g/L - fibrates alone to limit the risk of acute pancreatitis.
7. Follow-up - Liver biology after 15 days and monthly after.
- If transaminases levels is >5 N and/or muscular pain, treatment must be stopped
and CPK evaluation is required.
- Inform the patient of potential side effects so that he/she can alert his/her
primary care physician
Table 8 Hypolipidaemic diet, lifestyle and drugs
Dietary and life style guidance HMG-CoA reductase inhibitors (statins) Fibrates
- decrease the intake of saturated animal fat
(e.g. meats, cheese, sauces and fried foods).
- lower blood LDL-cholesterol levels by competitive inhibition
of HMG coenzyme A decreasing liver synthesis of cholesterol
- reduce triglyceride levels by
20-50%.
- favour omega-3 fatty acids (flaxseed, canola and
walnut oil, wheat germ, soya, mackerel, herring,
salmon…).
- improve survival rates in adults with variable cholesterol levels
(regardless of whether or not they have a history of coronary
heart disease)
- side effects:
- maintain a normal body weight and do
adapted regular physical exercise
- probably also beneficial in bone marrow recipients
o gallstones, transit and
muscle disorders.
- efficacy of rosuvastatin > atorvastatin (with the longest
half-life) > simvastatin > pravastatin and fluvastatin
(which are less expensive).
o Risk increased in
combination with a statin
or with altered kidney
function and with
ciclosporine.- statins other than fluva-, prava- and rosuvastatin, are
metabolized by cytochrome P450 (or CYP3A4) - Fenofibrate preferred to
gemfibrozil because of fewer
side effects, although it can
sometimes increase creatinine
levels.
- can thus interfere with many drugs*, calcineurin and mTOR
inhibitors, methotrexate, cimetidine, grapefruit juice.
- CYP3A4 inhibitors should be avoided in combination with
calcineurin inhibitors and statins
- Statins have liver, muscle toxicity: high-dose (>80 mg) statins
must not be prescribed.
*Main CYP3A4 inhibitors: calcium-blockers (diltiazem, verapamil), macrolides (erythromycin, clarithromycin), azole antifungals (itraco- and keto-conazole), antivirals
(rito-, indi-, nelfi- and ampe-navir).
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Table 10 Screening of the most frequent endocrine complications after allo-HSCT
Thyroid Disorder - TSH, free serum T4 at 6 months and yearly
- Clinical thyroid examination yearly
- Sonogram if clinical anomaly
- If abnormalities are detected, consider referral to an endocrinologist
Gonad dysfunction/Fertility 1. before allo-HSCT: conservation must be proposed as possible:
- Man: Sperm collection. After chemotherapy, it is possible if patient is not azoospermic.
- Female: ovary or oocyte freezing ; ovarian blocking by Gn-RH analogs
- Prepubertal: freezing of testicle pulp and ovarian tissu sample.
2. after allo-HSCT (first months): contraception is necessary (see Table 2)
3. after allo-SCT (second period):
- Woman: hormonal assessment and substitution indicated in 6–12 months. Gynecologic
evaluation yearly. Be careful between vaginal GVHD and menopausal symptoms.
- For male, dosage of testosterone if symptoms warrant and consider referral to specialist.
4. If pregnancy is discussed: 2 years between allo-HSCT and pregnancy is the minimum required.
Patient should be referred to specialist in assisted reproductive technologies/oncofertility.
Osteoporosis - Compensate a potential deficiency of calcium and vitamin D, especially if steroids.
- Screen and treat other causes of osteoporosis (hyperthyroidism, hyperparathyroidism,
hypogonadism)
- Dual photon densitometry (DEXA): if possible before and at least 1, 5 and 10 year after HSCT.
- Biphosphonate therapy if osteopenia or osteoporoses are established and if steroid
therapy >7.5 mg/day is prescribed more than 3 months
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disease, dyslipidemia, and diabetes, without any differ-
ence according to TBI or allogeneic versus autologous
graft [55]. This is confirmed by at least 2 other sudies
with an especially high risk (15%) in patients with mul-
tiple cardiovascular risk factors and pre-HSCT exposure
to anthracyclins or chest radiation [56], and in males
during the second and third decade [57].
This higher risk should prompt the physician to closely
monitor cardiovascular factors in these patients, particularly
over the long-term, once the initial disease phase has been
controlled, but in patients who can be as young as in their
third decade.
No epidemiological and treatment guidelines being
available after allo-HSCT, the cardiovascular risk of
these patients has been arbitrarily considered to be the
same as in a diabetic patient. Hence, LDL-cholesterol
must thus be below <1.3 g/L in all transplant recipients
and <1 g/L (or even <0.7 g/L) in secondary prevention
(i.e. in patients having presented cardiovascular com-
plications) and in primary prevention (i.e. in event-free
patients) in high-risk patients defined by: 1) family history
of early-onset vascular disease; 2) albuminuria >0.3 g/day
or kidney failure; 3) type 2 diabetes for the previous
10 years or more; 4) presenting two cardiovascular risk
factors [58].
Dietary and life style guidance as well as the different
available drugs and indications are summarized in Tables 8and 9. A few randomized trials and one systematic review
have shown a reduction of cardiovascular morbi-mortality
with statins in heart or renal transplant patients [59,60].
Finally, transplant recipients have an elevated cardio-
vascular risk, the management of which must be adapted
to suit the likely survival after treatment of an endocrine
disorder. Overall care management must be based on
the following five measures: 1) A balanced diet, exercise
and maintenance of a normal weight; 2) smoking cessa-
tion; 3) HbA1c <6.5%; 4) blood pressure <130/80 and 5)
LDL-cholesterol <1.3 g/L or 1.0 g/L, depending on the
cardiovascular risk.
Conclusion
Coexistence of multiple late sequelae is common in
HSCT survivors related to young age at the time of
HSCT, high radiation dose, and history of chronic
GVHD. The main endocrino-metabolic complications
are hypogonadism and infertility on the one hand and
diabetes with dyslipidemia and an increased cardiovas-
cular risk on the other hand. These conditions must be
screened for and treated (Tables 9 and 10). On-going
monitoring must take account of the increased risk of
secondary cancer (notably breast cancer, with an inci-
dence of 30% thirty years after radiotherapy). It is there-
fore essential to maintain long-term follow-up for
patients in whom the initial disease has cured.
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